Core Insights - Xiangsheng Medical reported a revenue of 236 million yuan and a net profit of 70 million yuan for the first half of 2025, with a non-recurring net profit of 64 million yuan [1] R&D Investment and Innovation - The company emphasizes high investment in R&D, with expenses amounting to 37.61 million yuan, representing 15.93% of total revenue, highlighting its commitment to innovation [2] - In the first half of 2025, Xiangsheng Medical obtained 13 new patent authorizations, including 7 invention patents, and filed 12 new intellectual property applications, with 5 being invention patent applications [2] - The total number of invention patents held by the company reached 158, including 11 valid international patents, indicating a deepening technological moat [2] - The company expanded its core technology matrix to 63 items, adding 2 new core technologies, and enhanced its "imaging + AI" dual-driven advantage [2] Product Development and AI Integration - Xiangsheng Medical developed core technologies such as "visual recognition and analysis" and "robotic motion precision control," integrating AI-assisted screening systems to launch the "AI + robotic scanning" series for mass screening of malignant tumors [3] - The "breast AI ultrasound robot" received a medical device testing report, establishing a full-cycle management system from screening to referral and treatment [3] - The integrated design of the technology includes a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, automatic ultrasound image transmission, and AI-assisted reading, facilitating large-scale screening and data tracking management [3] Global Market Expansion - In the first half of 2025, Xiangsheng Medical accelerated its international product registration, obtaining 43 new foreign market access licenses, thereby expanding its overseas market share [4] - The company’s entire series of digital color ultrasound diagnostic products passed the EU Medical Device Regulation (MDR) certification in July 2025 [4] - Xiangsheng Medical participated in over 70 global industry events and academic conferences to enhance brand exposure and clinical value [4] - The company hosted the "SonoGlobal2025" global agent conference in Dubai, Mexico, and Shanghai, launching the "Evergreen Elite Project" to upgrade core partners from "product sales" to "solution delivery" [4] Future Outlook - Xiangsheng Medical showcased its SonoFamily and SonoAI solutions at major events in Brazil, emphasizing the competitive edge of its ultra-thin, highly integrated ultrasound devices with 5G remote consultation capabilities [5] - The company aims to deepen its presence in the Brazilian market and accelerate global expansion, leveraging innovative technology to enhance local cooperation and improve regional diagnostic efficiency [5] - Looking ahead, Xiangsheng Medical plans to strengthen collaboration with global ultrasound experts to explore clinical needs and accelerate the integration of technological innovation with practical applications [5]